Article info

Download PDFPDF

1057 HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4–1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4–1BB activation
Free

Authors

Citation

Huang B, Du F, Lv X, et al
1057 HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4–1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4–1BB activation

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.